Eledon Announces Positive Topline Results from Phase 2a Trial of Tegoprubart Demonstrating Safety, Target Engagement, and Biomarker Response in Patients Living with Amyotrophic Lateral Sclerosis Tegoprubart was well-tolerated, with no drug-related serious adverse eventsDose dependent target engagement was demonstrated, and ALS associated pro-inflammatory biomarkers were both observed and...

Eledon Pharmaceuticals to Participate in 18th Annual Noble Capital Markets Investor Conference IRVINE, Calif., April 18, 2022 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), a patient-focused clinical stage biopharmaceutical company committed to the development of...

Eledon to Host Virtual R&D Day on Thursday, April 28, 2022 IRVINE, Calif., April 14, 2022 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), a patient-focused clinical stage biopharmaceutical company committed to the development of...

Eledon Pharmaceuticals Provides Corporate Update and 2022 Outlook Completed enrollment of all four cohorts in ongoing Phase 2a study with tegoprubart (AT-1501) in Amyotrophic Lateral Sclerosis (ALS) Announces USAN Approval of Generic Name “tegoprubart” for lead...

Eledon Pharmaceuticals to Participate in 11th Annual SVB Leerink Global Healthcare Conference IRVINE, Calif., Feb. 08, 2022 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), a patient-focused clinical stage biopharmaceutical company committed to the development of...